Open AccessMometasone Furoate for Adenoidal Hypertrophy in Adolescents
Author(s) -
SahinYilmaz Asli,
Celebi Saban,
Yilmaz H. Baki,
Oysu Cagatay
Publication year - 2012
Publication title -
otolaryngology–head and neck surgery
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.232
H-Index - 121
eISSN - 1097-6817
pISSN - 0194-5998
DOI - 10.1177/0194599812451426a402
Subject(s) - adenoid hypertrophy , medicine , mometasone furoate , placebo , adenoid , nasal administration , rhinorrhea , muscle hypertrophy , nose , nasal spray , crossover study , gastroenterology , anesthesia , surgery , corticosteroid , adenoidectomy , tonsillectomy , pathology , alternative medicine , immunology
Objective 1) To find out whether the symptoms attributable to adenoid hypertrophy in adolescents may be treated with intranasal mometasone furoate (MF) application. 2) To learn if adenoid hypertrophy in adolescents may decrease in size with intranasal MF. Method A prospective, double‐blind, randomized, crossover study was conducted in 28 subjects (12‐18 years) with adenoidal hypertrophy. Subjects used intranasal MF or placebo for a duration of 6 weeks with a washout period of 3 weeks. Subjective symptoms and adenoid size were evaluated. Results At the initiation of the study, there was no significant difference between the mean symptom scores for any of the sinonasal symptoms between the 2 treatment groups. Placebo users had no statistically significant reduction in their sinonasal symptoms ( P >. 05 for all) other than snoring ( P =. 011). MF users had a statistically significant reduction in all symptoms ( P <. 05 for all) other than coughing ( P =. 527). There was a significant difference between the 2 treatment groups in the mean posttreatment scores for total subjective symptom scoring and rhinorrhea ( P =. 031, P =. 012 resp). There was no significant difference in baseline endoscopy scores between the 2 treatment groups ( P =. 317). There was a significant reduction in nasal endoscopy scores in the MF group compared to placebo group ( P =. 034). Conclusion MF may have some advantage over placebo for the symptoms attributable to adenoid hypertrophy in adolescents. Intranasal MF decreases the size of the adenoid hypertrophy in this group of patients.